Results 21 to 30 of about 1,565,970 (254)
Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis [PDF]
The Korean Journal of Internal Medicine, 2022 Background/Aims The aim of this study was to investigate long-term post-discontinuation outcomes in patients with rheumatoid arthritis (RA) who had been treated with tumor necrosis factor-α inhibitors (TNF-αi) which was then discontinued.
Kichul Shin +14 more
doaj +1 more source
Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity [PDF]
The Korean Journal of Internal Medicine, 2020 Background/Aims The objective of this study was to compare changes in the simplified disease activity index (SDAI) between biologic (b) and conventional (c) disease-modifying antirheumatic drugs (DMARD) users with seropositive rheumatoid arthritis (RA ...
Kichul Shin +23 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background Cardiovascular disease is the most common cause of death in patients with rheumatoid arthritis. It is believed that using disease‐modifying antirheumatic drugs (DMARDs) to control inflammation can reduce the risk of cardiovascular disease.
Chung‐Yuan Hsu +8 more
doaj +1 more source
Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019 [PDF]
The Korean Journal of Internal Medicine, 2022 Background/Aims The preventive role of hydroxychloroquine (HCQ) on coronavirus disease 2019 (COVID-19) remains unclear. The aim of this study was to examine the effects of HCQ and other immunosuppressive drugs on the incidence of COVID-19.
Ji-Won Kim +5 more
doaj +1 more source
Effects of antirheumatic agents on cytokines [PDF]
Seminars in Arthritis and Rheumatism, 1996 A review of the literature concerning the effects of traditional antirheumatic drugs on cytokines and the cytokine and anticytokine approaches already used in the therapy of rheumatoid arthritis (RA) is presented. Many antirheumatic drugs are capable of cytokine modulation in vitro. Corticosteroids inhibit the transcription of a broad spectrum of genes
Barrera Rico, P. +3 more
openaire +4 more sources
BMC Rheumatology, 2020 Background Our study aimed to compare efficacy and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Limited) versus reference adalimumab (Humira®, Abbvie Inc.) in Indian patients with active rheumatoid arthritis (RA) concomitant on methotrexate ...
Shubhadeep Sinha +19 more
doaj +1 more source
Saudi Pharmaceutical Journal, 2020 Rheumatoid arthritis (RA) is an autoimmune inflammatory disease, which is accompanied by progressive joint damage and disability. The intolerability of conventional antirheumatic drugs by some patients necessitates the search for effective antirheumatic ...
Amany A. Azouz +2 more
doaj +1 more source
Frontiers in Medicine, 2022 BackgroundCOVID-19 may present different degrees of severity. Viral infections in patients with rheumatic inflammatory diseases (R-IMID) trend to present more severe disease.
David Martínez-López +10 more
doaj +1 more source
A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide, disease-modifying antirheumatic drugs, and etanercept [PDF]
Srpski Arhiv za Celokupno Lekarstvo, 2016 Introduction. A high platelet count, or thrombocytosis, is either a reactive process or a result of a myeloproliferative disorder. Ankylosing spondylitis is a chronic inflammatory rheumatic disease affecting the spine and sometimes peripheral ...
Zeremski Vanja +5 more
doaj +1 more source
Arthritis Research & Therapy, 2017 Background Biologic disease-modifying antirheumatic drugs (DMARDs) are increasingly used for rheumatoid arthritis (RA) treatment. However, little is known based on contemporary data about the factors associated with DMARDs and patterns of use of biologic
Yinzhu Jin +4 more
doaj +1 more source